Professor of Chemical Biology
My background is in organic chemistry and throughout my career I have worked on playing the science to biological questions. Our work on epigenetic histone deacetylase (HDAC) inhibitors led to the startup Karus Therapeutics that advanced two oncology products to clinical trials. I am currently on committees of the Royal Society of Chemistry and the International Union of Pure and Applied Chemistry and serve as editor of Pure and Applied Chemistry.
My current research interests are two-fold: